Derivation and Validation of an Optimal Neutrophil Gelatinase-Associated Lipocalin Cutoff to Predict Stage 2/3 Acute Kidney Injury (AKI) in Critically Ill Children.

NGAL acute kidney injury children neutrophil gelatinase-associated lipocalin

Journal

Kidney international reports
ISSN: 2468-0249
Titre abrégé: Kidney Int Rep
Pays: United States
ID NLM: 101684752

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 20 02 2024
revised: 07 04 2024
accepted: 06 05 2024
medline: 19 8 2024
pubmed: 19 8 2024
entrez: 19 8 2024
Statut: epublish

Résumé

Acute kidney injury (AKI) defined by changes in serum creatinine (SCr), or oliguria is associated with increased morbidity and mortality in children who are critically ill. We derived and validated a clinical cutoff value for urine neutrophil gelatinase-associated lipocalin (NGAL), in a prospective multicenter study of children who were critically ill. We report the clinical performance of urine NGAL (uNGAL) to aid in pediatric AKI risk assessment. Eligible subjects were aged ≥ 90 days to < 22 years, admitted to an intensive care unit (ICU), and had 1 or more of the following: mechanical ventilation, vasoactive medication administration, solid organ or bone marrow transplantation, or hypotension within 24-hours of admission. uNGAL was assessed within 24-hours of admission. The primary outcome was SCr-based stage 2/3 AKI presence at 48- to 72-hours. Twenty-five (12.3%) derivation study patients had stage 2/3 AKI at 48- to 72-hours. uNGAL concentration of 125 ng/ml was the optimal cutoff. Forty-seven (9.1%) validation study patients had stage 2/3 AKI at 48- to 72-hours. The area under the curve of a receiver operator characteristics curve (AUC-ROC) for uNGAL performance was 0.83 (95% confidence interval [CI]: 0.77-0.90). Performance characteristics were sensitivity 72.3% (95% CI: 57.4%-84.4%), specificity 86.3% (95% CI: 82.8%-89.3%), positive predictive value 34.7% (95% CI: 28.5%-41.5%), and negative predictive value 96.9% (95% CI: 95.1%-98.0%). These prospective, pediatric, multicenter studies demonstrate that uNGAL in the first 24-hours performs very well to predict Kidney Disease Improving Global Outcomes (KDIGO) stage 2/3 AKI at 48- to 72-hours into an ICU course. We suggest that a uNGAL cut point of 125 ng/ml can aid in the risk assessment for stage 2/3 AKI persistence or development.

Identifiants

pubmed: 39156146
doi: 10.1016/j.ekir.2024.05.010
pii: S2468-0249(24)01718-2
pmc: PMC11328761
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2443-2452

Informations de copyright

© 2024 International Society of Nephrology. Published by Elsevier Inc.

Auteurs

Stuart L Goldstein (SL)

Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Ayse Akcan-Arikan (A)

Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, USA.

Natasha Afonso (N)

Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, USA.

David J Askenazi (DJ)

Children's of Alabama, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Abby M Basalely (AM)

Cohen Children's Medical Center at Northwell Health, New York, USA.

Rajit K Basu (RK)

Lurie Children's Hospital, Northwestern University Feinberg School of Medicine, Illinois, Chicago, USA.

Hostensia Beng (H)

East Carolina University Brody School of Medicine, Greenville, North Carolina, USA.

Julie C Fitzgerald (JC)

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

Katja Gist (K)

Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Sarah Kizilbash (S)

University of Minnesota Children's Hospital Minneapolis, Minnesota, USA.

David Kwiatkowski (D)

Lucille Packard Children's Hospital Stanford University, Palo Alto, California, USA.

Christopher W Mastropietro (CW)

Riley Hospital for Children at Indiana University Health University of Indiana School of Medicine, Indianapolis, Indiana, USA.

Shina Menon (S)

Seattle Children's Hospital, Seattle, Washington, USA.

Megan SooHoo (M)

Children's Hospital of Colorado, Aurora, Colorado, USA.

Avram Z Traum (AZ)

Boston Children's Hospital, Boston, Massachusetts, USA.

Christopher A Bird (CA)

BioPorto Diagnostics, Copenhagen, Denmark, Europe.

Classifications MeSH